JO25567 phase II trial
Combining bevacizumab with erlotinib as first-line treatment for EGFR Mut+ NSCLC resulted in a significant improvement in PFS compared with single-agent erlotinib. This was the first evidence for the efficacy of the combination in this setting. 1
Study design and endpoints1
- JO25567 was a randomised phase II trial that took place across 30 centres in Japan.
- The trial compared erlotinib plus bevacizumab versus erlotinib alone as first-line treatment for EGFR Mut+ NSCLC.
ECOG PS (Eastern Co-operative Oncology Group performance status)
Key Results
Efficacy1
Patients who received erlotinib plus bevacizumab had significantly longer PFS than patients receiving single-agent erlotinib.
Safety1
The number of serious AEs and discontinuations were similar between treatment arms, but increased grade ≥3 AEs were observed in the combined treatment group.
Please click here for further safety data
- JO25567: common adverse events reported in the safety population (1/3)1
- JO25567: common adverse events reported in the safety population (2/3)1
- JO25567: common adverse events reported in the safety population (3/3)1